The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding.

• 首要效力观察终点是心血管事件的死亡，非致命性心肌梗死，或者非致命性中风。首要安全观察终点是大出血。